It was recently shown that palbociclib (CDK4/6 inhibitor), in addition to increasing the MHC class I expression, can alter the peptide-MHC repertoire in melanoma cell lines to reflect the intracellular response to CDK4/6 inhibition [152]. Here, CDK4 is linked to melanoma.